MedTrace Logo

Safety and Efficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting

NCT00661206 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4005

Last updated 2014-10-09

No results posted yet for this study

Summary

The purpose of this study is to determine whether a 6 month duration of clopidogrel therapy after DES implantation is not inferior to that of a 12 month therapy.

Conditions

Interventions

DRUG

Clopidogrel

Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day

DRUG

Placebo

Patients randomized in this group will receive placebo for 6 months.

Sponsors & Collaborators

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Adnan Kastrati, MD · Deutsches Herzzentrum Muenchen

  • Adnan Kastrati, MD · Deutsches Herzzentrum Muenchen

  • Jurriёn M ten Berg, MD · St. Antonius Hospital Nieuwegein, Department of Cardiology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • United States
  • Albania
  • Austria
  • Belgium
  • China
  • Denmark
  • Germany
  • Ireland
  • Italy
  • Japan
  • Netherlands
  • New Zealand
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00661206 on ClinicalTrials.gov